MHB036C

Phase 2Small molecule

MMinghui Pharmaceutical (Hangzhou) Ltd

MHB036C is one of 47 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Zolymbus

AbbVie

Preclinical

1 2

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 3

MHB036C

MMinghui Pharmaceutical (Hangzhou) Ltd

Phase 2

1 4

Acupan

YYonsei University

Preclinical

1 5

Paracetamol

GSK

Preclinical

1 6

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 7

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 8

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 9

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 10

Tianeptine

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Advanced Solid Tumor

NCT06373406

Q2 2030

Phase 1/2Recruiting

Lung Cancer

NCT07229599

Q3 2031

Phase 2Recruiting

Breast Cancer

NCT07130383

Clinical

Trials by Indication[1]

Advanced Solid Tumor1 trial

A Study of MHB036C for Advanced Solid Tumor

Active, not recruiting·MMinghui Pharmaceutical (Hangzhou) Ltd·Phase 1/2·NCT06373406·200 enrolled

Advanced or Metastatic Solid Tumors1 trial

Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors

Not yet recruiting·MMinghui Pharmaceutical Pty Ltd·Phase 1/2·NCT05642949·400 enrolled

Breast Cancer1 trial

A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors

Recruiting·MMinghui Pharmaceutical (Hangzhou) Ltd·Phase 2·NCT07130383·210 enrolled

Lung Cancer1 trial

A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer

Recruiting·MMinghui Pharmaceutical (Hangzhou) Ltd·Phase 1/2·NCT07229599·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for MHB036C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MHB036C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MHB036C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Minghui Pharmaceutical (Hangzhou) Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMinghui Pharmaceutical (Hangzhou) Ltd

MHB036C

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2030

Q3 2031

Trials by Indication[1]

Advanced Solid Tumor1 trial

Advanced or Metastatic Solid Tumors1 trial

Breast Cancer1 trial

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News